Login
$KALA
$3.77 -$0.06 (1.56%) After hours

$KALA 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

Arlington, MA, November 12, 2026 (GLOBE NEWSWIRE) — KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common...

09 Nov 2026 8-K: Results of Operations and Financial Condition

New York, November 9, 2026 – KALA BIO, Inc. (Nasdaq: KALA) today announced preliminary unaudited financial results for the quarter ended September 30, 2026.

03 Nov 2026 8-K: Submission of Matters to a Vote of Security Holders

A total of 14,459,767 shares of the Company’s Common Stock were present in person or represented by proxy at the Annual Meeting. At the Annual Meeting, stockholders voted in favor of the following items of business:

10 Sep 2026 8-K: Entry into a Material Definitive Agreement

CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED FROM THIS DOCUMENT BECAUSE IT IS BOTH (A) NOT MATERIAL AND (B) THE TYPE OF INFORMATION THAT THE COMPANY CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.

09 Sep 2026 8-K: Shareholder Director Nominations; Other Events

To the extent applicable, the information set forth below under Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.

28 Aug 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

23 Jul 2026 8-K: Other Events

Registration Statement on Form S-3, Registration No. 333-295667

07 May 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Kala Bio, Inc., a corporation organized under and existing by virtue of the General Corporation Law of the State of Delaware (“DGCL”), DOES HEREBY CERTIFY:

04 Mar 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

THIS PLATFORM DEVELOPMENT AND EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made and entered into as of March 3, 2026 (the “Effective Date”), by and between:

20 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

05 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

02 Feb 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +4 more

THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of January 30, 2026, by and between KALA BIO, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages ...

23 Jan 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

08 Jan 2026 8-K: Entry into a Material Definitive Agreement

KALA BIO, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows:

06 Jan 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

THIS VOTING AGREEMENT (this “Agreement”) is being signed on December 30, 2025 (the “Signature Date”) by and between Kala Bio, Inc. a Delaware corporation whose Common Stock is listed for trading on the Nasdaq (the “Proxy” or the “Company...

02 Jan 2026 8-K: Other Events

As previously disclosed in the Kala Bio, Inc. (the “Company”) Current Report on Form 8-K filed on November 25, 2025, the Company entered into a Loan Settlement Agreement (the “Settlement Agreement”) with Oxford Finance, LLC (“Oxford”) pu...

29 Dec 2025 8-K: Changes in Registrant's Certifying Accountant; Departure/Election of Directors or Officers; Compensation

As previously disclosed in the Company’s Current Report on Form 8-K filed on December 16, 2025, the audit committee of the Company’s Board of Directors approved the dismissal of Deloitte & Touche LLP as the Company’s independent register...

16 Dec 2025 8-K: Changes in Registrant's Certifying Accountant

We have read Item 4.01 of KALA BIO Inc.’s Form 8-K dated December 16, 2025, and have the following comments:

16 Dec 2025 8-K: Shareholder Director Nominations; Other Events

To the extent applicable, the information set forth below under Item 8.01 of this Current Report on Form 8-K “Notice of Annual Meeting” is incorporated by reference into this Item 5.08.

05 Dec 2025 8-K: Entry into a Material Definitive Agreement; Other Events

This Securities Purchase Agreement (this “Agreement”) is dated as of December 4, 2025, between KALA BIO, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its succe...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support